Of monkeys and men: Immunomic profiling of sera from humans and non-human primates resistant to schistosomiasis reveals novel potential vaccine candidates

Frontiers in Immunology

Volumn 6, Issue MAY, 2015, Pages

  Pearson, Mark S ^a   Becker, Luke ^a   Driguez, Patrick ^b   Young, Neil D ^c   Gaze, Soraya ^d   Mendes, Tiago ^e   Li, Xiao Hong ^f   Doolan, Denise L ^b   Midzi, Nicholas ^g   Mduluza, Takafira ^h   McManus, Donald P ^b   Wilson, R Alan ⁱ   Bethony, Jeffrey M ^j   Nausch, Norman ^k   Mutapi, Francisca ^k   Felgner, Philip L ^l   Loukas, Alex ^a  

^a JAMES COOK UNIVERSITY   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

^e FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^f CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^g National Institute for Health Research   (Zimbabwe)

^h UNIVERSITY OF ZIMBABWE   (Zimbabwe)

ⁱ UNIVERSITY OF YORK   (United Kingdom)

^j GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^k UNIVERSITY OF EDINBURGH   (United Kingdom)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Drug induced resistance; Human; Protein microarray; Schistosomiasis; Vaccine

Indexed keywords

IMMUNOGLOBULIN G1; PRAZIQUANTEL; VACCINE;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BIOINFORMATICS; CHILD; CONTROLLED STUDY; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREVALENCE; PROTEIN MICROARRAY; RHESUS MONKEY; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMIASIS;

EID: 84934269370     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00213     Document Type: Article

References (96)

1. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis (2006) 6(7):411-25. doi:10.1016/S1473-3099(06)70521-7
2. Butterworth AE, Hagan P. Immunity in human schistosomiasis. Parasitol Today (1987) 3(1):11-6. doi:10.1016/0169-4758(87)90091-3
3. Cheever AW, Torky AH, Shirbiney M. The relation of worm burden to passage of Schistosoma haematobium eggs in the urine of infected patients. Am J Trop Med Hyg (1975) 24(2):284-8.
4. Kjetland EF, Leutscher PD, Ndhlovu PD. A review of female genital schistosomiasis. Trends Parasitol (2012) 28(2):58-65. doi:10.1016/j.pt.2011.10.008
5. Moller H, Heseltine E, Vainio H. Working group report on schistosomes, liver flukes and Helicobacter pylori. Int J Cancer (1995) 60(5):587-9. doi:10.1002/ijc.2910600502
6. Secor WE. The effects of schistosomiasis on HIV/AIDS infection, progression and transmission. Curr Opin HIV AIDS (2012) 7(3):254-9. doi:10.1097/COH.0b013e328351b9e3
7. Harnett W. The anthelmintic action of praziquantel. Parasitol Today (1988) 4(5):144-6. doi:10.1016/0169-4758(88)90192-5
8. Harder A, Andrews P, Thomas H. Praziquantel: mode of action. Biochem Soc Trans (1987) 15(1):68-70.
9. Ottesen EA, Hiatt RA, Cheever AW, Sotomayor ZR, Neva FA. The acquisition and loss of antigen-specific cellular immune responsiveness in acute and chronic schistosomiasis in man. Clin Exp Immunol (1978) 33(1):37-47.
10. Grogan JL, Kremsner PG, van Dam GJ, Metzger W, Mordmuller B, Deelder AM, et al. Antischistosome IgG4 and IgE responses are affected differentially by chemotherapy in children versus adults. J Infect Dis (1996) 173(5):1242-7. doi:10.1093/infdis/173.5.1242
11. Grzych JM, Grezel D, Xu CB, Neyrinck JL, Capron M, Ouma JH, et al. IgA antibodies to a protective antigen in human schistosomiasis mansoni. J Immunol (1993) 150(2):527-35.
12. Mutapi F. Heterogeneities in anti-schistosome humoral responses following chemotherapy. Trends Parasitol (2001) 17(11):518-24. doi:10.1016/S1471-4922(01)02118-3
13. Mutapi F, Ndhlovu PD, Hagan P, Spicer JT, Mduluza T, Turner CM, et al. Chemotherapy accelerates the development of acquired immune responses to Schistosoma haematobium infection. J Infect Dis (1998) 178(1):289-93. doi:10.1086/517456
14. Bourke CD, Nausch N, Rujeni N, Appleby LJ, Mitchell KM, Midzi N, et al. Integrated analysis of innate, Th1, Th2, Th17, and regulatory cytokines identifies changes in immune polarisation following treatment of human schistosomiasis. J Infect Dis (2013) 208(1):159-69. doi:10.1093/infdis/jis524
15. Mduluza T, Mutapi F, Ruwona T, Kaluka D, Midzi N, Ndhlovu PD. Similar cellular responses after treatment with either praziquantel or oxamniquine in Schistosoma mansoni infection. Malawi Med J (2009) 21(4):176-82. doi:10.4314/mmj.v21i4.49642
16. Milner T, Reilly L, Nausch N, Midzi N, Mduluza T, Maizels R, et al. Circulating cytokine levels and antibody responses to human Schistosoma haematobium: IL-5 and IL-10 levels depend upon age and infection status. Parasite Immunol (2010) 32(11-12):710-21. doi:10.1111/j.1365-3024.2010.01235.x
17. Dunne DW, Butterworth AE, Fulford AJ, Kariuki HC, Langley JG, Ouma JH, et al. Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to reinfection. Eur J Immunol (1992) 22(6):1483-94. doi:10.1002/eji.1830220622
18. Naus CW, van Dam GJ, Kremsner PG, Krijger FW, Deelder AM. Human IgE, IgG subclass, and IgM responses to worm and egg antigens in schistosomiasis haematobium: a 12-month study of reinfection in Cameroonian children. Clin Infect Dis (1998) 26(5):1142-7. doi:10.1086/520310
19. Satti MZ, Lind P, Vennervald BJ, Sulaiman SM, Daffalla AA, Ghalib HW. Specific immunoglobulin measurements related to exposure and resistance to Schistosoma mansoni infection in Sudanese canal cleaners. Clin Exp Immunol (1996) 106(1):45-54. doi:10.1046/j.1365-2249.1996.d01-810.x
20. Gaze S, Driguez P, Pearson MS, Mendes T, Doolan DL, Trieu A, et al. An immunomics approach to schistosome antigen discovery: antibody signatures of naturally resistant and chronically infected individuals from endemic areas. PLoS Pathog (2014) 10(3):e1004033. doi:10.1371/journal.ppat.1004033
21. Sabah AA, Fletcher C, Webbe G, Doenhoff MJ. Schistosoma mansoni: chemotherapy of infections of different ages. Exp Parasitol (1986) 61(3):294-303. doi:10.1016/0014-4894(86)90184-0
22. Correa-Oliveira R, Caldas IR, Gazzinelli G. Natural versus drug-induced resistance in Schistosoma mansoni infection. Parasitol Today (2000) 16(9):397-9. doi:10.1016/S0169-4758(00)01740-3
23. Mitchell KM, Mutapi F, Savill NJ, Woolhouse ME. Protective immunity to Schistosoma haematobium infection is primarily an anti-fecundity response stimulated by the death of adult worms. Proc Natl Acad Sci U S A (2012) 109(33):13347-52. doi:10.1073/pnas.1121051109
24. Wilson S, Jones FM, van Dam GJ, Corstjens PL, Riveau G, Fitzsimmons CM, et al. Human Schistosoma haematobium antifecundity immunity is dependent on transmission intensity and associated with immunoglobulin G1 to worm-derived antigens. J Infect Dis (2014) 210(12):2009-16. doi:10.1093/infdis/jiu374
25. Black CL, Mwinzi PN, Muok EM, Abudho B, Fitzsimmons CM, Dunne DW, et al. Influence of exposure history on the immunology and development of resistance to human schistosomiasis mansoni. PLoS Negl Trop Dis (2010) 4(3):e637. doi:10.1371/journal.pntd.0000637
26. Black CL, Steinauer ML, Mwinzi PN, Evan Secor W, Karanja DM, Colley DG. Impact of intense, longitudinal retreatment with praziquantel on cure rates of schistosomiasis mansoni in a cohort of occupationally exposed adults in western Kenya. Trop Med Int Health (2009) 14(4):450-7. doi:10.1111/j.1365-3156.2009.02234.x
27. Mutapi F, Burchmore R, Mduluza T, Foucher A, Harcus Y, Nicoll G, et al. Praziquantel treatment of individuals exposed to Schistosoma haematobium enhances serological recognition of defined parasite antigens. J Infect Dis (2005) 192(6):1108-18. doi:10.1086/432553
28. Mutapi F, Burchmore R, Mduluza T, Midzi N, Turner CM, Maizels RM. Age-related and infection intensity-related shifts in antibody recognition of defined protein antigens in a schistosome-exposed population. J Infect Dis (2008) 198(2):167-75. doi:10.1086/589511
29. Braschi S, Curwen RS, Ashton PD, Verjovski-Almeida S, Wilson A. The tegument surface membranes of the human blood parasite Schistosoma mansoni: a proteomic analysis after differential extraction. Proteomics (2006) 6(5):1471-82. doi:10.1002/pmic.200500368
30. Braschi S, Wilson RA. Proteins exposed at the adult schistosome surface revealed by biotinylation. Mol Cell Proteomics (2006) 5(2):347-56. doi:10.1074/mcp. M500287-MCP200
31. Cardoso FC, Macedo GC, Gava E, Kitten GT, Mati VL, de Melo AL, et al. Schistosoma mansoni tegument protein Sm29 is able to induce a Th1-type of immune response and protection against parasite infection. PLoS Negl Trop Dis (2008) 2(10):e308. doi:10.1371/journal.pntd.0000308
32. Cardoso FC, Pacifico RN, Mortara RA, Oliveira SC. Human antibody responses of patients living in endemic areas for schistosomiasis to the tegumental protein Sm29 identified through genomic studies. Clin Exp Immunol (2006) 144(3):382-91. doi:10.1111/j.1365-2249.2006.03081.x
33. Tran MH, Pearson MS, Bethony JM, Smyth DJ, Jones MK, Duke M, et al. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis. Nat Med (2006) 12(7):835-40. doi:10.1038/nm1430
34. Wilson RA, Langermans JA, van Dam GJ, Vervenne RA, Hall SL, Borges WC, et al. Elimination of Schistosoma mansoni adult worms by rhesus macaques: basis for a therapeutic vaccine? PLoS Negl Trop Dis (2008) 2(9):e290. doi:10.1371/journal.pntd.0000290
35. Cheever AW, Powers KG. Schistosoma mansoni infection in rhesus monkeys: changes in egg production and egg distribution in prolonged infections in intact and splenectomized monkeys. Ann Trop Med Parasitol (1969) 63(1):83-93.
36. McMullen DB, Ritchie LS, Oliver-Gonzalez J, Knight WB. Schistosoma mansoni in Macaca mulatta. Long-term studies on the course of primary and challenge infections. Am J Trop Med Hyg (1967) 16(5):620-7.
37. Driguez P, Doolan DL, Molina DM, Loukas A, Trieu A, Felgner PL, et al. Protein microarrays for parasite antigen discovery. Methods Mol Biol (2015) 1201:221-33. doi:10.1007/978-1-4939-1438-8_13
38. Crompton PD, Kayala MA, Traore B, Kayentao K, Ongoiba A, Weiss GE, et al. A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci U S A (2010) 107(15):6958-63. doi:10.1073/pnas.1001323107
39. Doolan DL, Mu Y, Unal B, Sundaresh S, Hirst S, Valdez C, et al. Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics (2008) 8(22):4680-94. doi:10.1002/pmic.200800194
40. Trieu A, Kayala MA, Burk C, Molina DM, Freilich DA, Richie TL, et al. Sterile protective immunity to malaria is associated with a panel of novel P. falciparum antigens. Mol Cell Proteomics (2011) 10(9):M111007948. doi:10.1074/mcp. M111.007948
41. Driguez P, Doolan DL, Loukas A, Felgner PL, McManus DP. Schistosomiasis vaccine discovery using immunomics. Parasit Vectors (2010) 3:4. doi:10.1186/1756-3305-3-4
42. McWilliam HE, Driguez P, Piedrafita D, McManus DP, Meeusen EN. Discovery of novel Schistosoma japonicum antigens using a targeted protein microarray approach. Parasit Vectors (2014) 7:290. doi:10.1186/1756-3305-7-290
43. Young ND, Jex AR, Li B, Liu S, Yang L, Xiong Z, et al. Whole-genome sequence of Schistosoma haematobium. Nat Genet (2012) 44(2):221-5. doi:10.1038/ng.1065
44. Bourke CD, Nausch N, Rujeni N, Appleby LJ, Trottein F, Midzi N, et al. Cytokine responses to the anti-schistosome vaccine candidate antigen glutathione-S-transferase vary with host age and are boosted by praziquantel treatment. PLoS Negl Trop Dis (2014) 8(5):e2846. doi:10.1371/journal.pntd.0002846
45. Eberl M, al-Sherbiny M, Hagan P, Ljubojevic S, Thomas AW, Wilson RA. A novel and sensitive method to monitor helminth infections by faecal sampling. Acta Trop (2002) 83(2):183-7. doi:10.1016/S0001-706X(02)00089-X
46. Cai YC, Xu JF, Steinmann P, Chen SH, Chu YH, Tian LG, et al. Field comparison of circulating antibody assays versus circulating antigen assays for the detection of schistosomiasis japonica in endemic areas of China. Parasit Vectors (2014) 7:138. doi:10.1186/1756-3305-7-138
47. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics (2014) 30(15):2114-20. doi:10.1093/bioinformatics/btu170
48. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods (2012) 9(4):357-9. doi:10.1038/nmeth.1923
49. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics (2011) 12:323. doi:10.1186/1471-2105-12-323
50. Karmakar S, Zhang W, Ahmad G, Torben W, Alam MU, Le L, et al. Use of an Sm-p80-based therapeutic vaccine to kill established adult schistosome parasites in chronically infected baboons. J Infect Dis (2014) 209(12):1929-40. doi:10.1093/infdis/jiu031
51. Riveau G, Deplanque D, Remoue F, Schacht AM, Vodougnon H, Capron M, et al. Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis. PLoS Negl Trop Dis (2012) 6(7):e1704. doi:10.1371/journal.pntd.0001704
52. Pearson MS, Pickering DA, McSorley HJ, Bethony JM, Tribolet L, Dougall AM, et al. Enhanced protective efficacy of a chimeric form of the schistosomiasis vaccine antigen Sm-TSP-2. PLoS Negl Trop Dis (2012) 6(3):e1564. doi:10.1371/journal.pntd.0001564
53. Arnon R, Espinoza-Ortega B, Tarrab-Hazdai R. Acetylcholinesterase of Schistosoma mansoni-an antigen of functional implications. Mem Inst Oswaldo Cruz (1987) 82(Suppl 4):163-70. doi:10.1590/S0074-02761987000800028
54. Zhu Y, Ren J, Harn DA, Si J, Yu C, Ming X, et al. Protective immunity induced with 23 kDa membrane protein dna vaccine of Schistosoma japonicum Chinese strain in infected C57BL/6 mice. Southeast Asian J Trop Med Public Health (2003) 34(4):697-701.
55. Bhardwaj R, Krautz-Peterson G, Da'dara A, Tzipori S, Skelly PJ. Tegumental phosphodiesterase SmNPP-5 is a virulence factor for schistosomes. Infect Immun (2011) 79(10):4276-84. doi:10.1128/IAI.05431-11
56. Krautz-Peterson G, Simoes M, Faghiri Z, Ndegwa D, Oliveira G, Shoemaker CB, et al. Suppressing glucose transporter gene expression in schistosomes impairs parasite feeding and decreases survival in the mammalian host. PLoS Pathog (2010) 6(6):e1000932. doi:10.1371/journal.ppat.1000932
57. Da'dara AA, Faghiri Z, Krautz-Peterson G, Bhardwaj R, Skelly PJ. Schistosome Na, K-ATPase as a therapeutic target. Trans R Soc Trop Med Hyg (2013) 107(2):74-82. doi:10.1093/trstmh/trs020
58. Cook RM, Carvalho-Queiroz C, Wilding G, LoVerde PT. Nucleic acid vaccination with Schistosoma mansoni antioxidant enzyme cytosolic superoxide dismutase and the structural protein filamin confers protection against the adult worm stage. Infect Immun (2004) 72(10):6112-24. doi:10.1128/IAI.72.10.6112-6124.2004
59. Barker RH Jr, Srivastava BS, Suri P, Goldberg M, Knopf PM. Immunoprecipitation analysis of radiolabelled protein antigens biosynthesized in vitro by S. mansoni. I. Identification of antigens uniquely recognized by protective antibodies. J Immunol (1985) 134(2):1192-201.
60. Moloney NA, Webbe G. Antibody is responsible for the passive transfer of immunity to mice from rabbits, rats or mice vaccinated with attenuated Schistosoma japonicum cercariae. Parasitology (1990) 100(Pt 2):235-9. doi:10.1017/S0031182000061230
61. Ahmad G, Zhang W, Torben W, Ahrorov A, Damian RT, Wolf RF, et al. Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic. J Infect Dis (2011) 204(9):1437-49. doi:10.1093/infdis/jir545
62. Fitzsimmons CM, Jones FM, Pinot de Moira A, Protasio AV, Khalife J, Dickinson HA, et al. Progressive cross-reactivity in IgE responses: an explanation for the slow development of human immunity to schistosomiasis? Infect Immun (2012) 80(12):4264-70. doi:10.1128/IAI.00641-12
63. Hagan P, Blumenthal UJ, Dunn D, Simpson AJ, Wilkins HA. Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium. Nature (1991) 349(6306):243-5. doi:10.1038/349243a0
64. Diemert DJ, Pinto AG, Freire J, Jariwala A, Hamilton R, Periago MV, et al. Generalized urticaria induced by the Na-ASP-2 hookworm vaccine-implications for the development of vaccines against helminths. J Allerg Clin Immunol (2012) 130(1):169-76.e6. doi:10.1016/j.jaci.2012.04.027
65. Higon M, Cowan G, Nausch N, Cavanagh D, Oleaga A, Toledo R, et al. Screening trematodes for novel intervention targets: a proteomic and immunological comparison of Schistosoma haematobium, Schistosoma bovis and Echinostoma caproni. Parasitology (2011) 138(12):1607-19. doi:10.1017/S0031182011000412
66. Trottein F, Godin C, Pierce RJ, Sellin B, Taylor MG, Gorillot I, et al. Inter-species variation of schistosome 28-kDa glutathione S-transferases. Mol Biochem Parasitol (1992) 54(1):63-72. doi:10.1016/0166-6851(92)90095-2
67. Taylor JB, Vidal A, Torpier G, Meyer DJ, Roitsch C, Balloul JM, et al. The glutathione transferase activity and tissue distribution of a cloned Mr28K protective antigen of Schistosoma mansoni. EMBO J (1988) 7(2):465-72.
68. Balloul JM, Pierce RJ, Grzych JM, Capron A. In vitro synthesis of a 28 kilodalton antigen present on the surface of the schistosomulum of Schistosoma mansoni. Mol Biochem Parasitol (1985) 17(1):105-14. doi:10.1016/0166-6851(85)90131-8
69. Johnson KA, Angelucci F, Bellelli A, Herve M, Fontaine J, Tsernoglou D, et al. Crystal structure of the 28 kDa glutathione S-transferase from Schistosoma haematobium. Biochemistry (2003) 42(34):10084-94. doi:10.1021/bi034449r
70. Remoue F, Rogerie F, Gallissot MC, Guyatt HL, Neyrinck JL, Diakkhate MM, et al. Sex-dependent neutralizing humoral response to Schistosoma mansoni 28GST antigen in infected human populations. J Infect Dis (2000) 181(5):1855-9. doi:10.1086/315454
71. Dougall AM, Skwarczynski M, Khoshnejad M, Chandrudu S, Daly NL, Toth I, et al. Lipid core peptide targeting the cathepsin D hemoglobinase of Schistosoma mansoni as a component of a schistosomiasis vaccine. Hum Vaccin Immunother (2014) 10(2):399-409. doi:10.4161/hv.27057
72. Hotez PJ, Diemert D, Bacon KM, Beaumier C, Bethony JM, Bottazzi ME, et al. The human hookworm vaccine. Vaccine (2013) 31(Suppl 2):B227-32. doi:10.1016/j.vaccine.2012.11.034
73. Tran MH, Freitas TC, Cooper L, Gaze S, Gatton ML, Jones MK, et al. Suppression of mRNAs encoding tegument tetraspanins from Schistosoma mansoni results in impaired tegument turnover. PLoS Pathog (2010) 6(4):e1000840. doi:10.1371/journal.ppat.1000840
74. Shi F, Zhang Y, Ye P, Lin J, Cai Y, Shen W, et al. Laboratory and field evaluation of Schistosoma japonicum DNA vaccines in sheep and water buffalo in China. Vaccine (2001) 20(3-4):462-7. doi:10.1016/S0264-410X(01)00340-1
75. Jones AK, Bentley GN, Oliveros Parra WG, Agnew A. Molecular characterization of an acetylcholinesterase implicated in the regulation of glucose scavenging by the parasite Schistosoma. FASEB J (2002) 16(3):441-3. doi:10.1096/fj.01-0683fje
76. Kasny M, Mikes L, Hampl V, Dvorak J, Caffrey CR, Dalton JP, et al. Chapter 4. Peptidases of trematodes. Adv Parasitol (2009) 69:205-97. doi:10.1016/S0065-308X(09)69004-7
77. Horn M, Fajtova P, Rojo Arreola L, Ulrychova L, Bartosova-Sojkova P, Franta Z, et al. Trypsin-and chymotrypsin-like serine proteases in Schistosoma mansoni-'the undiscovered country'. PLoS Negl Trop Dis (2014) 8(3):e2766. doi:10.1371/journal.pntd.0002766
78. Gobert GN, Tran MH, Moertel L, Mulvenna J, Jones MK, McManus DP, et al. Transcriptional changes in Schistosoma mansoni during early schistosomula development and in the presence of erythrocytes. PLoS Negl Trop Dis (2010) 4(2):e600. doi:10.1371/journal.pntd.0000600
79. Protasio AV, Dunne DW, Berriman M. Comparative study of transcriptome profiles of mechanical-and skin-transformed Schistosoma mansoni schistosomula. PLoS Negl Trop Dis (2013) 7(3):e2091. doi:10.1371/journal.pntd.0002091
80. Sanchez-Pulido L, Martin-Belmonte F, Valencia A, Alonso MA. MARVEL: a conserved domain involved in membrane apposition events. Trends Biochem Sci (2002) 27(12):599-601. doi:10.1016/S0968-0004(02)02229-6
81. Douglas LM, Wang HX, Konopka JB. The MARVEL domain protein Nce102 regulates actin organization and invasive growth of Candida albicans. mBio (2013) 4(6):e723-713. doi:10.1128/mBio.00723-13
82. El Ridi R, Tallima H, Selim S, Donnelly S, Cotton S, Gonzales Santana B, et al. Cysteine peptidases as schistosomiasis vaccines with inbuilt adjuvanticity. PLoS One (2014) 9(1):e85401. doi:10.1371/journal.pone.0085401
83. Knox DP, Redmond DL, Newlands GF, Skuce PJ, Pettit D, Smith WD. The nature and prospects for gut membrane proteins as vaccine candidates for Haemonchus contortus and other ruminant trichostrongyloids. Int J Parasitol (2003) 33(11):1129-37. doi:10.1016/S0020-7519(03)00167-X
84. Pearson MS, Ranjit N, Loukas A. Blunting the knife: development of vaccines targeting digestive proteases of blood-feeding helminth parasites. Biol Chem (2010) 391(8):901-11. doi:10.1515/BC.2010.074
85. Dakshinamoorthy G, Munirathinam G, Stoicescu K, Reddy MV, Kalyanasundaram R. Large extracellular loop of tetraspanin as a potential vaccine candidate for filariasis. PLoS One (2013) 8(10):e77394. doi:10.1371/journal.pone.0077394
86. Dang Z, Yagi K, Oku Y, Kouguchi H, Kajino K, Matsumoto J, et al. A pilot study on developing mucosal vaccine against alveolar echinococcosis (AE) using recombinant tetraspanin 3: vaccine efficacy and immunology. PLoS Negl Trop Dis (2012) 6(3):e1570. doi:10.1371/journal.pntd.0001570
87. Iborra S, Soto M, Carrion J, Nieto A, Fernandez E, Alonso C, et al. The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice. Infect Immun (2003) 71(11):6562-72. doi:10.1128/IAI.71.11.6562-6572.2003
88. Chatterjee S, Singh S, Sohoni R, Singh NJ, Vaidya A, Long C, et al. Antibodies against ribosomal phosphoprotein P0 of Plasmodium falciparum protect mice against challenge with Plasmodium yoelii. Infect Immun (2000) 68(7):4312-8. doi:10.1128/IAI.68.7.4312-4318.2000
89. Chatterjee S, Singh S, Sohoni R, Kattige V, Deshpande C, Chiplunkar S, et al. Characterization of domains of the phosphoriboprotein P0 of Plasmodium falciparum. Mol Biochem Parasitol (2000) 107(2):143-54. doi:10.1016/S0166-6851(99)00226-1
90. Buck AH, Coakley G, Simbari F, McSorley HJ, Quintana JF, Le Bihan T, et al. Exosomes secreted by nematode parasites transfer small RNAs to mammalian cells and modulate innate immunity. Nat Commun (2014) 5:5488. doi:10.1038/ncomms6488
91. Marcilla A, Trelis M, Cortes A, Sotillo J, Cantalapiedra F, Minguez MT, et al. Extracellular vesicles from parasitic helminths contain specific excretory/secretory proteins and are internalized in intestinal host cells. PLoS One (2012) 7(9):e45974. doi:10.1371/journal.pone.0045974
92. Pearce EJ, MacDonald AS. The immunobiology of schistosomiasis. Nat Rev Immunol (2002) 2(7):499-511. doi:10.1038/nri843
93. Farnell EJ, Tyagi N, Ryan S, Chalmers IW, Pinot de Moira A, Jones FM, et al. Known allergen structures predict Schistosoma mansoni IgE-binding antigens in human infection. Front Immunol (2015) 6:26. doi:10.3389/fimmu.2015.00026
94. Wan D, Ludolf F, Alanine DG, Stretton O, Ali Ali E, Al-Barwary N, et al. Use of humanised rat basophilic leukaemia cell line RS-ATL8 for the assessment of allergenicity of Schistosoma mansoni proteins. PLoS Negl Trop Dis (2014) 8(9):e3124. doi:10.1371/journal.pntd.0003124
95. Zhan B, Santiago H, Keegan B, Gillespie P, Xue J, Bethony J, et al. Fusion of Na-ASP-2 with human immunoglobulin Fcgamma abrogates histamine release from basophils sensitized with anti-Na-ASP-2 IgE. Parasite Immunol (2012) 34(8-9):404-11. doi:10.1111/j.1365-3024.2012.01371.x
96. Davies DH, Chun S, Hermanson G, Tucker JA, Jain A, Nakajima R, et al. T cell antigen discovery using soluble vaccinia proteome reveals recognition of antigens with both virion and nonvirion association. J Immunol (2014) 193(4):1812-27. doi:10.4049/jimmunol.1400663